000282604 001__ 282604
000282604 005__ 20251211161805.0
000282604 0247_ $$2doi$$a10.1186/s42466-025-00453-5
000282604 0247_ $$2pmid$$apmid:41361909
000282604 0247_ $$2pmc$$apmc:PMC12687528
000282604 037__ $$aDZNE-2025-01362
000282604 041__ $$aEnglish
000282604 082__ $$a610
000282604 1001_ $$0P:(DE-2719)9003388$$aPreßler, Hannah$$b0$$eFirst author$$udzne
000282604 245__ $$aParaneoplastic Lambert-Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic review.
000282604 260__ $$a[London]$$bBioMed Central$$c2025
000282604 3367_ $$2DRIVER$$aarticle
000282604 3367_ $$2DataCite$$aOutput Types/Journal article
000282604 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765466141_17919
000282604 3367_ $$2BibTeX$$aARTICLE
000282604 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282604 3367_ $$00$$2EndNote$$aJournal Article
000282604 520__ $$aParaneoplastic Lambert-Eaton myasthenic syndrome (pLEMS) is well-established in small-cell lung cancer (SCLC), but data on other malignancies are limited. We aimed to define the clinical phenotype of pLEMS in non-SCLC cancers (non-SCLC-pLEMS) relative to SCLC-associated LEMS (SCLC-pLEMS) and autoimmune LEMS (aiLEMS).Retrospective analysis was conducted to compare patients with SCLC-pLEMS, aiLEMS and non-SCLC-pLEMS from the European LEMS registry, and further non-SCLC-pLEMS cases were identified by a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.The registry included 72 aiLEMS, 12 SCLC-pLEMS, and 11 non-SCLC-pLEMS patients. LEMS preceded cancer diagnosis in 33% of SCLC-pLEMS (median 2 months) and 30% of non-SCLC-pLEMS (median 15 months), was concurrent in 25% and 30% and followed tumor diagnosis in the remainder. At study enrollement, Quantitative Myasthenia Gravis (QMG) scores were higher in SCLC-pLEMS (median 12, range 1-24) with recent tumor therapy initiation (median 3 months), and lower in non-SCLC-pLEMS (median 6, range 0-19), with longer (median 12 months) or completed tumor therapy, and aiLEMS (median 5, range 0-23). During follow-up, QMG improved with tumor therapy, and worsened with recurrence/progression in pLEMS groups. After completion of cancer treatment, QMG values in SCLC-pLEMS (median 6, range 0-19) and non-SCLC-pLEMS (median 5, range 1-22) were comparable to each other and to aiLEMS (median 7, range 0-29). Ataxia was significantly more frequent in SCLC-pLEMS (64%) and non-SCLC-pLEMS (55%) than in aiLEMS (19%, p = 0.006 and p = 0.024). Another 115 literature-reported non-SCLC-pLEMS cases were identified (total n = 126, comprising 137 tumors). Most common were non-small cell lung cancer (NSCLC) (n = 25, 18%), Merkel cell carcinoma (n = 18, 13%) and lymphoproliferative disorders (n = 15, 11%). In 52 literature-reported LEMS patients with outcome data, 88% partially or fully recovered after tumor therapy, leaving the paraneoplastic origin uncertain in many.Our results suggest that, beyond SCLC, other tumors can trigger pLEMS. Compared with aiLEMS, non-SCLC-pLEMS and SCLC-pLEMS showed a higher frequency of ataxia, and LEMS severity tended to reflect tumor treatment status, while disease severity becomes comparable across subtypes after cancer therapy. The frequent improvement of symptoms with tumor-directed treatment supports extended screening beyond SCLC and timely management.
000282604 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282604 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282604 650_7 $$2Other$$aAtaxia
000282604 650_7 $$2Other$$aCancer treatment
000282604 650_7 $$2Other$$aLambert-Eaton myasthenic syndrome
000282604 650_7 $$2Other$$aParaneoplastic
000282604 650_7 $$2Other$$aTumor
000282604 7001_ $$aHaddy, Imène$$b1
000282604 7001_ $$aDaugherty, Claire$$b2
000282604 7001_ $$aPostila, Ville$$b3
000282604 7001_ $$aMeisel, Andreas$$b4
000282604 773__ $$0PERI:(DE-600)2947493-0$$a10.1186/s42466-025-00453-5$$gVol. 7, no. 1, p. 95$$n1$$p95$$tNeurological research and practice$$v7$$x2524-3489$$y2025
000282604 8564_ $$uhttps://pub.dzne.de/record/282604/files/DZNE-2025-01362.pdf$$yRestricted
000282604 8564_ $$uhttps://pub.dzne.de/record/282604/files/DZNE-2025-01362.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282604 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003388$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000282604 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282604 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-30
000282604 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000282604 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:42:53Z
000282604 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:42:53Z
000282604 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:42:53Z
000282604 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-10T15:42:53Z
000282604 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000282604 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-30
000282604 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000282604 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-30
000282604 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-30
000282604 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000282604 980__ $$ajournal
000282604 980__ $$aEDITORS
000282604 980__ $$aVDBINPRINT
000282604 980__ $$aI:(DE-2719)1810003
000282604 980__ $$aUNRESTRICTED